Protect the graft. Protect the repair.
XenMatrix™ AB is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2
true
- Overview
- Products & Accessories
- EIFU & Resources
- FAQ
true
Protection when and where it's needed
XenMatrix™ AB is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2 It uses a combination of well-characterized antibiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair.
Protective Antibacterial Coating
- The XenMatrix™ AB coating uses Rifampin and Minocycline, an antibacterial combination with demonstrated clinical results in other medical devices.3
- Protects the graft prior to neovascularization.
- Provides protection from biofilm formation caused by MRSA and E. coli.
- Shown to reduce bacterial colonization in 5 different medical devices:
- Central Venous Catheters (CVC)
- External Ventricular Drain Catheters (EVD)
- Hemodialysis Catheters
- Inflatable Penile Prostheses (IPP)
- Cardiovascular Implantable Electronic Device (CIED) Envelopes
- These devices coated with Rifampin and Minocycline are well-studied in clinical literature; 30 publications including 67,000 patients and 6 randomized controlled trials.3
- No instances of microbial resistance to the combination of Rifampin and Minocycline have been reported.
- No complications or adverse events due to the antibiotic content for on-label use have been reported.
1 IMS Data, Q2 2014, 510K search, fda.gov.
2 Preclincal data on file; results may not correlate to clinical performance.
3 Literature search and analysis of Rifampin and Minocycline coated medical devices. Data on file. 2014
Indications:
Intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue, including: abdominal plastic and reconstructive surgery; muscle flap reinforcement; hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias. The Rifampin and Minocycline coating has been shown in preclinical in vitro and in vivo testing to reduce or inhibit microbial colonization on the device. The claim of reduction of bacterial colonization of the device has not been established with human clinical data, nor has a clinical impact associated with this claim been demonstrated.
Contraindications:
- XenMatrix™ AB Surgical Graft should not be used on patients with known sensitivity to porcine products.
- Do not use in patients with allergy, history of allergy or hypersensitivity to tetracyclines or rifamycins or other components in the device.
- Do not use in pregnant or nursing women.
- The contraindications, warnings and precautions regarding the use of the antimicrobial agents Rifampin (a derivative of rifamycinB) and Minocycline (a derivative of tetracycline) apply and should be considered when using this device. See FDA’s drug labeling database for Rifampin and Minocycline labeling.
The use of this product in patients with compromised hepatic function should be carefully considered since Rifampin can cause additional stress to hepatic metabolism. Implantation of this device would not result in detectable systemic concentrations of Rifampin or Minocycline. - Patients implanted with the largest product size (30 cm x 45 cm) are calculated to receive a one time total dose of approximately 327 mg each of Rifampin and Minocycline. This is in contrast to typical systemic treatment doses, which are 600 mg for Rifampin and 200 mg for Minocycline administered multiple times per day, over several days to several months.
Warnings:
- This device is not indicated for the treatment of infection. If an infection develops, treat the infection aggressively.
- To minimize recurrences when repairing hernias, the graft should be large enough to provide sufficient overlap beyond the margins of the defect on all sides.
- Prior to use, carefully examine package and product to verify neither is damaged and that all seals are intact. Do not use if the package is damaged or open.
- Postoperative signs of toxicity, as possibly evidenced by worsening renal or hepatic function, or an allergic reaction that is unrelated to other therapy is an indication to consider removal of XenMatrix™ AB Surgical Graft.
- Do not use this product in patients with allergy, history of allergy or hypersensitivity to tetracyclines or rifamycins or other components of the device.
- The safety and performance of XenMatrix™ AB Surgical Graft in pediatric patients has not been evaluated.
Precautions:
Do not alter practice of pre-, peri-, or postoperative administration of local or systemic antibiotics.
Adverse Reactions:
Potential complications with the use of any prosthesis may include, but are not limited to, allergic reaction or hypersensitivity to device materials or antimicrobial coating, seroma, infection, inflammation, adhesion, fistula formation, hematoma, and recurrence of tissue defect.
WARNING: This product can expose you to Rifampin and Minocycline HCL, which are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.
BD-14768
-
XenMatrix™ AB Surgical Graft, Rectangle, 6.3 in x 2.4 in (6 cm x 16 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 5.9 in x 9.8 in (15 cm x 25 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 9.8 in x 11.8 in (25 cm x30 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 7.5 in x 11 in (19 cm x 28 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 7.9 in x 9.8 in (20 cm x 25 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 7.9 in x 7.9 in (20 cm x 20 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 11.8 in x 17.7 in (30 cm x 45 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 3.1 in x 6.3 in (8 cm x 16 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 3.9 in x 7.9 in (10 cm x 20 cm)
-
XenMatrix™ AB Surgical Graft, Square, 3.9 in x 3.9 in (10 cm x 10 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 2.4 in x 3.1 in (6 cm x 8 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 3.9 in x 11 in (10 cm x 28 cm)
-
XenMatrix™ AB Surgical Graft, Square, 3.1 in x 3.1 in (8cm x 8cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 7.9 in x 15.7 in (20 cm x 40 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 5.9 in x 11.8 in (15 cm x 30 cm)
-
XenMatrix™ AB Surgical Graft, Square, 11.8 in x 11.8 in (30 cm x 30 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 5.9 in x 7.9 in (15 cm x 20 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 3.9 in x 2.4 in (6 cm x 10 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 7.5 in x 13.8 in (19 cm x 35 cm)
-
XenMatrix™ AB Surgical Graft, Square, 2.4 in x 2.4 in (6 cm x 6 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 9.8 in x 15.7 in (25 cm x 40 cm)
-
XenMatrix™ AB Surgical Graft, Rectangle, 3.9 in x 5.9 in (10 cm x 15 cm)
1 IMS Data, Q2 2014, 510K search, fda.gov.
2 Preclincal data on file; results may not correlate to clinical performance.
3 Literature search and analysis of Rifampin and Minocycline coated medical devices. Data on file. 2014
Indications:
Intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue, including: abdominal plastic and reconstructive surgery; muscle flap reinforcement; hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias. The Rifampin and Minocycline coating has been shown in preclinical in vitro and in vivo testing to reduce or inhibit microbial colonization on the device. The claim of reduction of bacterial colonization of the device has not been established with human clinical data, nor has a clinical impact associated with this claim been demonstrated.
Contraindications:
XenMatrix™ AB Surgical Graft should not be used on patients with known sensitivity to porcine products.
Do not use in patients with allergy, history of allergy or hypersensitivity to tetracyclines or rifamycins or other components in the device. Do not use in pregnant or nursing women.
The contraindications, warnings and precautions regarding the use of the antimicrobial agents Rifampin (a derivative of rifamycinB) and Minocycline (a derivative of tetracycline) apply and should be considered when using this device. See FDA’s drug labeling database for Rifampin and Minocycline labeling.
The use of this product in patients with compromised hepatic function should be carefully considered since Rifampin can cause additional stress to hepatic metabolism. Implantation of this device would not result in detectable systemic concentrations of Rifampin or Minocycline.
Patients implanted with the largest product size (30 cm x 45 cm) are calculated to receive a one time total dose of approximately 327 mg each of Rifampin and Minocycline. This is in contrast to typical systemic treatment doses, which are 600 mg for Rifampin and 200 mg for Minocycline administered multiple times per day, over several days to several months.
Warnings:
This device is not indicated for the treatment of infection. If an infection develops, treat the infection aggressively.
To minimize recurrences when repairing hernias, the graft should be large enough to provide sufficient overlap beyond the margins of the defect on all sides.
Prior to use, carefully examine package and product to verify neither is damaged and that all seals are intact. Do not use if the package is damaged or open.
Postoperative signs of toxicity, as possibly evidenced by worsening renal or hepatic function, or an allergic reaction that is unrelated to other therapy is an indication to consider removal of XenMatrix™ AB Surgical Graft.
Do not use this product in patients with allergy, history of allergy or hypersensitivity to tetracyclines or rifamycins or other components of the device.
The safety and performance of XenMatrix™ AB Surgical Graft in pediatric patients has not been evaluated.
Precautions:
Do not alter practice of pre-, peri-, or postoperative administration of local or systemic antibiotics.
Adverse Reactions:
Potential complications with the use of any prosthesis may include, but are not limited to, allergic reaction or hypersensitivity to device materials or antimicrobial coating, seroma, infection, inflammation, adhesion, fistula formation, hematoma, and recurrence of tissue defect.
WARNING:
This product can expose you to Rifampin and Minocycline HCL, which are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.true
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
Training
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
Learn more
Events
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
Learn more
Case Studies
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Learn more
1 IMS Data, Q2 2014, 510K search, fda.gov.
2 Preclincal data on file; results may not correlate to clinical performance.
3 Literature search and analysis of Rifampin and Minocycline coated medical devices. Data on file. 2014
Indications:
Intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue, including: abdominal plastic and reconstructive surgery; muscle flap reinforcement; hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias. The Rifampin and Minocycline coating has been shown in preclinical in vitro and in vivo testing to reduce or inhibit microbial colonization on the device. The claim of reduction of bacterial colonization of the device has not been established with human clinical data, nor has a clinical impact associated with this claim been demonstrated.
Contraindications:
XenMatrix™ AB Surgical Graft should not be used on patients with known sensitivity to porcine products.
Do not use in patients with allergy, history of allergy or hypersensitivity to tetracyclines or rifamycins or other components in the device. Do not use in pregnant or nursing women.
The contraindications, warnings and precautions regarding the use of the antimicrobial agents Rifampin (a derivative of rifamycinB) and Minocycline (a derivative of tetracycline) apply and should be considered when using this device. See FDA’s drug labeling database for Rifampin and Minocycline labeling.
The use of this product in patients with compromised hepatic function should be carefully considered since Rifampin can cause additional stress to hepatic metabolism. Implantation of this device would not result in detectable systemic concentrations of Rifampin or Minocycline.
Patients implanted with the largest product size (30 cm x 45 cm) are calculated to receive a one time total dose of approximately 327 mg each of Rifampin and Minocycline. This is in contrast to typical systemic treatment doses, which are 600 mg for Rifampin and 200 mg for Minocycline administered multiple times per day, over several days to several months.
Warnings:
This device is not indicated for the treatment of infection. If an infection develops, treat the infection aggressively.
To minimize recurrences when repairing hernias, the graft should be large enough to provide sufficient overlap beyond the margins of the defect on all sides.
Prior to use, carefully examine package and product to verify neither is damaged and that all seals are intact. Do not use if the package is damaged or open.
Postoperative signs of toxicity, as possibly evidenced by worsening renal or hepatic function, or an allergic reaction that is unrelated to other therapy is an indication to consider removal of XenMatrix™ AB Surgical Graft.
Do not use this product in patients with allergy, history of allergy or hypersensitivity to tetracyclines or rifamycins or other components of the device.
The safety and performance of XenMatrix™ AB Surgical Graft in pediatric patients has not been evaluated.
Precautions:
Do not alter practice of pre-, peri-, or postoperative administration of local or systemic antibiotics.
Adverse Reactions:
Potential complications with the use of any prosthesis may include, but are not limited to, allergic reaction or hypersensitivity to device materials or antimicrobial coating, seroma, infection, inflammation, adhesion, fistula formation, hematoma, and recurrence of tissue defect.
WARNING:
This product can expose you to Rifampin and Minocycline HCL, which are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.true
false
true
